A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2019
At a glance
- Drugs RG 6149 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Genentech
- 06 Feb 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 15 Jan 2019 to 7 Feb 2019.
- 09 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Dec 2018 to 15 Jan 2019.
- 10 Dec 2018 Status changed from not yet recruiting to recruiting.